Supernus Pharmaceuticals, Inc.
LSE: 0LB2.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jack A. Khattar
- Employees
- 674
- Headquarters
- Rockville, United States
- IPO year
- 2018
- Market cap
- $2.9B
- Website
- https://www.supernus.com
Loading 0LB2…
Loading profile data…Frequently asked questions about 0LB2
What does Supernus Pharmaceuticals, Inc. (0LB2.L) do?
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
Where does 0LB2.L trade?
Supernus Pharmaceuticals, Inc. (0LB2.L) trades on the London Stock Exchange.
What sector is 0LB2.L in?
Supernus Pharmaceuticals, Inc. (0LB2.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Supernus Pharmaceuticals, Inc.?
Jack A. Khattar is the chief executive officer of Supernus Pharmaceuticals, Inc. (0LB2.L).
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered in United States.
Does 0LB2.L pay a dividend?
Supernus Pharmaceuticals, Inc. (0LB2.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0LB2.L go public?
Supernus Pharmaceuticals, Inc. (0LB2.L) completed its initial public offering in 2018.